These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20424535)

  • 1. [Experience accumulated in hospital setting with levofloxacin, in monotherapy and in association therapy].
    Petrosillo N
    Infez Med; 2009 Dec; 17 Suppl 5():36-44. PubMed ID: 20424535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic experience with levofloxacin in pneumonia and COPD].
    Blasi F
    Infez Med; 2009 Dec; 17 Suppl 5():23-8. PubMed ID: 20424533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guidelines for treatment of pneumonia in intensive care units].
    Emmi V
    Infez Med; 2005; Suppl():7-17. PubMed ID: 16801748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin: an updated review of its use in the treatment of bacterial infections.
    Hurst M; Lamb HM; Scott LJ; Figgitt DP
    Drugs; 2002; 62(14):2127-67. PubMed ID: 12269858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.
    Anderson VR; Perry CM
    Drugs; 2008; 68(4):535-65. PubMed ID: 18318569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levofloxacin for the treatment of respiratory tract infections.
    Torres A; Liapikou A
    Expert Opin Pharmacother; 2012 Jun; 13(8):1203-12. PubMed ID: 22594848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin in the treatment of community-acquired pneumonia.
    Noreddin AM; Elkhatib WF
    Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
    Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
    BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM; Davis NB; Wu SC; Kahn J
    Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Observational study investigating the use of levofloxacin in ICU patients].
    Alvarez-Lerma F; Palomar M; Olaechea P; León C; Sánchez M; Bermejo B;
    Enferm Infecc Microbiol Clin; 2004 Apr; 22(4):220-6. PubMed ID: 15056438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From cystitis to bacterial prostatitis: experience with levofloxacin].
    Mirone V
    Infez Med; 2009 Dec; 17 Suppl 5():29-35. PubMed ID: 20424534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
    Scheen AJ
    Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
    Grossman RF; Rotschafer JC; Tan JS
    Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.